Skip to content

Artivion AORT Additional Paid-In Capital

Additional Paid-In Capital at other companies

LeMaitre Vascular logo
LeMaitre VascularLMAT
$233.45M+7.5%
Medtronic logo
MedtronicMDT
$20.93B+0.4%
ITG
Integer HoldingsITGR
$755.87M+0.2%
IAR
Integra LifeSciencesIART
$1.34B+1.3%
TFX
TeleflexTFX
$815.81M+4.4%
Globus Medical logo
Globus MedicalGMED
$3.21B+5.0%

Other financials

Income statement

See full
Revenue$116.3M+17.5%
Gross profit$75.4M+18.7%
Operating income$5.8M+170%
Net income$1.4M+381%
EPS (diluted)$0.03+400%

Balance sheet

See full
Cash & equivalents$55.8M+47.9%
Total debt$258.2M-28.8%
Total equity$450.5M+53.1%
Total assets$883.2M+11.6%

Cash flow

See full
Operating cash flow$1.2M+107%
CapEx$8.0M+120%
Free cash flow-$6.8M+66.7%

Valuation

See full
Market cap$1.07B-22.7%
Enterprise value$1.27B-25.5%
P/E91.5×
P/S2.3×-1.2×

Profitability

See full
Gross margin64.6%+0.6pp
Operating margin8.2%+4.1pp
Net margin2.5%+1.5pp
FCF margin-0.1%-2.5pp

Returns & leverage

See full
Return on equity3.1%+1.8pp
Debt / equity0.6×-0.7×
Current ratio3.9×-1.7×

Where this comes from

Reported directly by Artivion in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: Artivion’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Artivion's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Artivion's additional paid-in capital?
Artivion (AORT) reported additional paid-in capital of $526.26M in Q1 2026.
How has Artivion's additional paid-in capital changed year-over-year?
Artivion's additional paid-in capital increased by 35.3% year-over-year, from $388.83M to $526.26M.
What is the long-term trend for Artivion's additional paid-in capital?
Over 5 years (2020 to 2025), Artivion's additional paid-in capital has grown at a 10.3% compound annual growth rate (CAGR), from $316.19M to $516.6M.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.